Humacyte (HUMA) Short term Debt (2020 - 2025)

Humacyte (HUMA) has reported Short term Debt for 6 consecutive years, with $3.1 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $3.1 million in Q3 2025; TTM through Sep 2025 was $3.1 million, a N/A change from a year earlier, with the FY2024 full-year figure at $885000.0, changed N/A from the prior year.
• Short term Debt was $3.1 million for Q3 2025 at Humacyte, up from $2.1 million in the prior quarter.
• Over five years, Short term Debt peaked at $12.9 million in Q1 2023 and troughed at $885000.0 in Q4 2024.
• A 5-year average of $4.7 million and a median of $3.5 million in 2021 frame the typical range for Short term Debt.
• The widest YoY moves for Short term Debt: up 10.21% in 2022, down 10.21% in 2022.
• Over 5 years, Short term Debt stood at $3.9 million in 2021, then surged by 120.39% to $8.6 million in 2022, then soared by 50.01% to $12.9 million in 2023, then tumbled by 93.12% to $885000.0 in 2024, then jumped by 247.12% to $3.1 million in 2025.
• The last three Short term Debt figures came in at $3.1 million (Q3 2025), $2.1 million (Q2 2025), and $1.7 million (Q1 2025), per Business Quant data.